scispace - formally typeset
A

Anat Galor

Researcher at University of Miami

Publications -  223
Citations -  6596

Anat Galor is an academic researcher from University of Miami. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 37, co-authored 172 publications receiving 4707 citations. Previous affiliations of Anat Galor include Bascom Palmer Eye Institute & Cleveland Clinic.

Papers
More filters
Journal ArticleDOI

TFOS DEWS II pain and sensation report

Carlos Belmonte, +16 more
- 01 Jul 2017 - 
TL;DR: Pain associated with mechanical, chemical, and thermal heat stimulation of the ocular surface is mediated by trigeminal ganglion neurons, while cold thermoreceptors detect wetness and reflexly maintain basal tear production and blinking rate, thereby evoking dryness sensations and pain.
Journal ArticleDOI

Antiplatelet and anticoagulant therapy in patients with giant cell arteritis

Michael S. Lee, +3 more
- 01 Oct 2006 - 
TL;DR: Antiplatelet or anticoagulant therapy may reduce the risk of ischemic events in patients with GCA and an increased risk of bleeding complications was not observed.
Journal ArticleDOI

Current Thoughts in Fungal Keratitis: Diagnosis and Treatment

Zubair Ansari, +5 more
- 01 Sep 2013 - 
TL;DR: This review will discuss current diagnostic modalities of fungal keratitis and will particularly focus on treatment regimens, and explore future therapeutic models and critique the potential benefit of each.
Journal ArticleDOI

Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Anat Galor, +3 more
- 01 Dec 2006 - 
TL;DR: Infliximab was more effective than etanercept in the treatment of recalcitrant uveitis and decreased the use of topical steroids.
Journal ArticleDOI

Comparison of Antimetabolite Drugs as Corticosteroid-Sparing Therapy for Noninfectious Ocular Inflammation

Anat Galor, +7 more
- 01 Oct 2008 - 
TL;DR: The data suggest that the time to control of ocular inflammation is faster with mycophenolate than with methotrexate, and that azathioprine therapy has a higher rate of treatment-related side effects compared with the other 2 agents.